Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study

Tanaka, Ikuko; Tanaka, Yoshiya; Soen, Satoshi; Oshima, Hisaji

doi:10.1007/s00774-020-01171-5

Cited by 11 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased trabecular BMD and bone surface to volume ratio was observed through HRpQCT imaging in patients treated with teriparatide, compared with risedronate 103 . While noninferiority of weekly teriparatide against weekly alendronate could not be confirmed after 72 weeks, 105 spinal BMD increased by 5.1% with teriparatide and 4.0% with alendronate; fracture incidence was similar in the two groups 105 . There are no human studies assessing the efficacy of abaloparatide in GIO.…”

Section: Denosumabmentioning

confidence: 99%

Challenges in the diagnosis and management of glucocorticoid‐induced osteoporosis in younger and older adults

Herath

Langdahl

Ebeling

et al. 2021

Clinical Endocrinology

View full text Add to dashboard Cite

Objective Glucocorticoids constitute a considerable risk for developing osteoporosis in both younger and older adults. However, currently available bone imaging modalities and fracture‐risk assessment tools do not adequately capture the dramatic changes in bone microarchitecture, heterogeneity of glucocorticoid exposure, the impact of chronic disease and other osteoporosis risk factors on the assessment of osteoporosis in these individuals. Design A narrative review is presented, following a systematic search of the literature from 2000 to 2021. Results Our current appreciation of glucocorticoid‐induced osteoporosis (GIO) is focused on older populations, with limited evidence to guide the investigation, risk assessment and treatment in premenopausal women and men less than 50 years. The impact of the underlying chronic disease on secondary osteoporosis in these younger adults is also poorly understood. Conclusion Through this narrative review, we provide a comprehensive overview of and recommendations for optimising the management of this common cause of secondary osteoporosis younger and older adults.

show abstract

Section: Denosumabmentioning

confidence: 99%